MIM
PSTX

MetLife Investment Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

MetLife Investment Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,083
Closed -$404K – 2851
2024
Q4 		$404K Buy
42,083
+2,617
+7% +$13.7K ﹤0.01% 1915
2024
Q3 		$113K Hold
39,466
– – ﹤0.01% 2577
2024
Q2 		$115K Buy
39,466
+15,821
+67% +$43.3K ﹤0.01% 2537
2024
Q1 		$75.4K Sell
23,645
-12,664
-35% -$42.2K ﹤0.01% 2651
2023
Q4 		$122K Hold
36,309
– – ﹤0.01% 2502
2023
Q3 		$86.4K Hold
36,309
– – ﹤0.01% 2652
2023
Q2 		$63.9K Buy
+36,309
New +$92.7K ﹤0.01% 2873
2021
Q2 		– Sell
-14,683
Closed -$140K – 2500
2021
Q1 		$140K Buy
+14,683
New +$144K ﹤0.01% 2212

Other funds holding PSTX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MetLife Investment Management's PSTX Position: Q1 2025 in Review

MetLife Investment Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 42,083 shares — an estimated $404K sold.

MetLife Investment Management first reported a position in PSTX in Q1 2021 and held it in 8 quarters. The position peaked at $404K in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

  • MetLife Investment Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • MetLife Investment Management sold 42,083 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $404K.
  • MetLife Investment Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
  • MetLife Investment Management's Poseida Therapeutics, Inc. Common Stock position peaked at $404K in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.